Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
397030
vs
K
KOSPI 200
Over the past 12 months, AprilBio Co Ltd has underperformed KOSPI 200, delivering a return of -53% compared to KOSPI 200's +116% growth.
Stocks Performance
397030 vs KOSPI 200
Performance Gap
397030 vs KOSPI 200
Performance By Year
397030 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AprilBio Co Ltd
Glance View
AprilBio is a South Korean biopharmaceutical company that develops protein-based medicines, with a focus on long-acting biologic drugs. Its work centers on designing and advancing drug candidates that can treat serious diseases more effectively than older injectable proteins that wear off quickly. The company sits in the drug development part of the healthcare value chain, turning laboratory research into medicines that can move into testing and, if approved, into hospital use. The company’s business is built around two main activities: developing its own drug pipeline and working with partners on biologic projects. It sells its know-how, research services, and any licensed or partnered drug rights to other pharma companies, while its own medicines can eventually generate sales through hospital and pharmacy channels after approval. Like many biotech firms, it often relies on collaboration payments and licensing deals before products reach the market. What makes AprilBio different is its emphasis on specialized biologic engineering rather than traditional small-molecule drugs. That means it focuses on making protein medicines last longer in the body and work more conveniently for patients, which can matter a lot in chronic or hard-to-treat diseases. For beginner investors, the key point is that AprilBio is not a broad healthcare company; it is a focused biotech developer trying to turn a few science-based drug programs into commercial medicines.